12-10-2017 22:43 CET Notification of ownership in ALK
27-9-2017 09:00 CET ALK’s partner, Torii, gains approval for Japanese cedar SLIT-tablet in Japan
21-9-2017 19:39 CET ALK acts on French injunction by accelerating investments in its quality system at the French manufacturing facility
14-9-2017 13:15 CET Successful Phase III trial for ALK’s tree allergy SLIT-tablet
4-9-2017 17:19 CET Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
21-8-2017 18:59 CET ALK to accelerate launches of ODACTRA™ in the USA / ACARIZAX® in Canada
16-8-2017 07:45 CET Six-month interim report (Q2) 2017
8-8-2017 15:39 CET Release date of six-month interim report (Q2) 2017 and audio cast
31-7-2017 10:11 CET Management change at ALK
1-6-2017 12:19 CET Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
9-5-2017 07:45 CET Three-month interim report (Q1) 2017
4-5-2017 21:07 CET ALK's HDM SLIT-tablet, ACARIZAX®, approved in Canada
3-5-2017 10:28 CET Release date of three-month interim report (Q1) 2017 and audio cast
16-4-2017 20:00 CET ACARIZAX® approved in Europe for use in adolescent patients with house dust mite-induced allergic rhinitis
24-3-2017 08:00 CET ALK’s partner, Torii, submits paediatric registration application for the house dust mite SLIT-tablet in Japan
23-3-2017 15:02 CET Report on Management's transactions with ALK-Abelló A/S B shares and associated securities
23-3-2017 14:44 CET Grant of share options and performance shares to members of the Board of Management and key employees
16-3-2017 12:55 CET Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
15-3-2017 17:13 CET Annual General Meeting in ALK-Abelló A/S held on 15 March 2017
7-3-2017 15:43 CET Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff